# Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease

Study · id `cardio:ct-nct03164785` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03164785](<https://clinicaltrials.gov/study/NCT03164785>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03164785

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

## Technical summary

Registry record NCT03164785. Randomized; no masking; primary purpose treatment. Start 2017-07-24 (actual); primary completion 2020-09-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 202 participants (enrolled count; ClinicalTrials.gov record NCT03164785, source copy `cardio:ctgov-nct03164785-2024-01-03`, retrieved 2026-10-26)
- Started: 2017-07-24 (actual) (ClinicalTrials.gov record NCT03164785, source copy `cardio:ctgov-nct03164785-2024-01-03`, retrieved 2026-10-26)
- Primary completion: 2020-09-26 (actual) (ClinicalTrials.gov record NCT03164785, source copy `cardio:ctgov-nct03164785-2024-01-03`, retrieved 2026-10-26)
- Completion: 2022-12-08 (actual) (ClinicalTrials.gov record NCT03164785, source copy `cardio:ctgov-nct03164785-2024-01-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03164785, source copy `cardio:ctgov-nct03164785-2024-01-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03164785-2024-01-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease
- Condition: Type 2 Diabetes Mellitus
- Condition: Diabetic Kidney Disease
- Intervention (Drug): Jinshuibao Capsule
- Lead sponsor: Second Xiangya Hospital of Central South University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Second Xiangya Hospital of Central South University (`cardio:org-second-xiangya-hospital-of-central-south-university`)

## Provenance

Content hash: 7c0d243d647cb83efc8bc76e592e9d08e0ea80e1459baf6f35879e02a70c2411
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
